Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma

NCT07724457 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

271

Enrollment

NIH

Sponsor class

Conditions

Recurrent Burkitt Lymphoma
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
Refractory Burkitt Lymphoma
Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Biopsy
DRUG: Carboplatin
PROCEDURE: Computed Tomography
DRUG: Cyclophosphamide
DRUG: Cytarabine
DRUG: Doxorubicin
DRUG: Etoposide
BIOLOGICAL: Glofitamab
DRUG: Ifosfamide
PROCEDURE: Lumbar Puncture
PROCEDURE: Magnetic Resonance Imaging
DRUG: Methotrexate
BIOLOGICAL: Obinutuzumab
PROCEDURE: Positron Emission Tomography
DRUG: Prednisone
BIOLOGICAL: Rituximab
BIOLOGICAL: Rituximab and Hyaluronidase Human
OTHER: Survey Administration
DRUG: Vincristine

Sponsor

National Cancer Institute (NCI)